Citations

Showing 10 of 108104 citations.

Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
Nowsheen, Somaira , Park, Jae Yoon, Villarraga, Hector R. , Ruddy, Kathryn J. , Herrmann, Joerg , Aziz, Khaled , Ruddy, Kathryn Jean, Park, Jae Yoon, Lerman, Amir

Mayo Clinic

Journal of the American Heart Association | September 16, 2018 | Volume: 7 | Issue: 15 | Pages: No page available

10.1161/jaha.118.008637 | PMID 30371238 Get It

Background Trastuzumab is life‐extending therapy for breast cancer patients overexpressing the human epidermal growth factor receptor 2 ( HER 2+), but has known cardiotoxic risk. We sought to determine if trastuzumab can be administered to patients with reduced baseline cardiac function at no higher cardiotoxicity risk than in those with normal cardiac function at baseline. Methods and Results We performed a retrospective study of women treated with trastuzumab for human epidermal growth factor receptor 2 breast cancer at Mayo Clinic Rochester between January 1, 2000 and August 31, 2015 with pre‐ and on‐therapy echocardiograms available for review. A left ventricular ejection fraction (LVEF) <53% was considered abnormal, and a ≥10% decline in LVEF as evidence of cardiotoxicity based on the criteria of the American Society of Echocardiography. A total of 428 women were identified; 408 had a normal cardiac function ( LVEF 63.4±5%) and 20 had an impaired cardiac function ( LVEF 45.4±7%) before trastuzumab. Seven women (35%) with reduced LVEF at baseline had a ≥10% reduction in LVEF , compared with 179 (43.9%) of those with normal LVEF before trastuzumab initiation ( P = NS ). Symptomatic heart failure developed more often in patients with reduced versus normal baseline LVEF (25% versus 4.2%, P <0.05). After adjusting for patient age and breast cancer disease stage, survival rates over 5 years from time of diagnosis were found to be lower for patients with reduced baseline LVEF compared with patients with normal baseline LVEF ( P <0.001); the adjusted proportion of patients surviving at 5 years for those with low LVEF at baseline was 79% and for those with normal LVEF was 93%. Conclusions Women undergoing trastuzumab therapy for breast cancer with impaired baseline cardiac function experience no higher risk of LVEF decline, but more frequently develop symptomatic heart failure. While trastuzumab could be considered, these patients should be co‐managed by a cardiologist.
Response by Wong et al to Letter Regarding Article, “Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation”
Wong, Ka Lam , Kremers, Walter K. , Pereira, Naveen L. , Kremers, Walter K , Smith, Byron H.

Mayo Clinic

Circulation | September 16, 2018 | Volume: 137 | Issue: 17 | Pages: 1872-1873

10.1161/circulationaha.117.032883 | PMID 29685937 Get It

PS01.054: GASTROESOPHAGEAL REFLUX DISEASE PHENOTYPES IN THE MODERN ERA: CLINICAL, ENDOSCOPIC, MANOMETRIC AND PH TESTING PROPERTIES
Hoversten, Patrick , Katzka, David A. , Halland, Magnus

Mayo Clinic

Diseases of the Esophagus | September 16, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 65-65

10.1093/dote/doy089.ps01.054 Get It

Abstract Background Reflux phenotypes have classically been divided into supine, upright, and bipositional predominant reflux. Recent data on clinical, endoscopic, and manometric features in these patient groups are scant and most prior reports occurred prior to the advent of high resolution impedance manometry and prolonged wireless pH monitoring. We aimed to evaluate the distribution, demographic, manometric, and endoscopic characteristics of the reflux phenotypes in this modern era of testing. Methods Patients who had esophageal physiology testing at a single tertiary care center over a one year period were retrospectively reviewed for demographic, clinical, endoscopic, manometric and pH impedance data. We included consecutive patients who had undergone pH-impedance or wireless pH testing with an EGD within 6 months. Results 139 patients were included and 91 (65.5%) patients were women was mean age of 51.9 + /- 15.2 years and mean BMI of 29.1 + /- 6.4. The most common reflux pattern was bipositional (46% of patients), followed by supine (25%). Baseline characteristics, endoscopic and manometric data across groups are included in Table 1. Barrett's esophagus was most common in the non-acid group. Endoscopically, esophagitis was most common in the supine and bipositional groups. Manometric findings were similar across groups. Conclusion The epidemiology of GERD patients appears to be changing as evidenced by a higher mean BMI than in the largest prior study from 1999. Despite demographic changes in GERD and more widespread use of advanced esophageal physiology testing, the manometric and endoscopic characteristics of GERD phenotypes remains fairly similar. Disclosure All authors have declared no conflicts of interest.
Early Natural History of Spontaneous Coronary Artery Dissection
Waterbury, Thomas M. , Eleid, Mackram F. , Bell, Malcolm R. , Best, Patricia J.M. , Lewis, Bradley R., Rihal, Charanjit S. , Gulati, Rajiv , Tweet, Marysia S. , Hayes, Sharonne N. , Lerman, Amir , Singh, Mandeep , Rihal, Charanjit S. , Gersh, Bernard J.

Mayo Clinic

Circulation: Cardiovascular Interventions | September 16, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circinterventions.118.006772 | PMID 30354594 Get It

Background: Risks and mechanisms of extension of conservatively managed spontaneous coronary artery dissection (SCAD) remain incompletely understood. Study objectives were to (1) evaluate mechanisms of early SCAD evolution through serial angiographic analysis, and (2) determine predictors of early SCAD progression. Methods and Results: Retrospective registry study of patients with SCAD managed with an initial conservative strategy (n=240). Patients who experienced significant SCAD progression within 14 days, defined as clinical worsening plus new critical coronary obstruction on repeat angiography, were compared with remaining controls. A total of 42 of 240 (17.5%) experienced significant SCAD progression after index conservative approach; 91% by day 6. Isolated intramural hematoma (IMH) at baseline (no intimal dissection) was observed more frequently in those experiencing progression compared with controls (69.1% versus 44.4%; P =0.004). Multivariable predictors of SCAD progression included lesion severity, multivessel involvement, and isolated IMH. To investigate mechanisms of SCAD evolution, all repeat angiograms ≤14 days were compared with corresponding baselines (n=82 patient angiogram pairs). Of those with isolated IMH at baseline, 20% developed intimal dissection at repeat study. IMH was associated with greater longitudinal lesion extension (11.5 versus 2.8 mm; P =0.01), worsening Thrombolysis in Myocardial Infarction flow (−0.8 versus 0.1; P =0.003), and a nonsignificant lower rate of angiographic improvement (20.0% versus 31.3%; P =0.16) compared with the group with baseline intimal dissection. Optical coherence tomography subgroup analysis (n=17) indicated intimo-medial thickness to be lowest at the midpoint of IMH. Conclusions: Conservatively managed SCAD carries a 1:6 hazard for serious deterioration within 6 days. The risk was higher in those with isolated IMH at baseline. IMH often precedes development of intimal dissection, which has implications for mechanisms of SCAD.
Incidence of squamous cell carcinoma in oral lichen planus: a 25-year population-based study
Laniosz, Valerie, Torgerson, Rochelle R. , Ramos‐Rodriguez, Alvaro J. , Janice, E., Mara, Kristin C. , Weaver, Amy L. , Bruce, Alison J., Ma, Janice E, Mara, Kristin C

Mayo Clinic

International Journal of Dermatology | September 15, 2018 | Volume: 58 | Issue: 3 | Pages: 296-301

10.1111/ijd.14215 | PMID 30216435 Get It

Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance
Belleville, Sylvie , Cantilon, Marc, Chételat, Gaël , Ewers, Michael , Franzmeier, Nicolai , Kempermann, Gerd , Okonkwo, Ozioma C. , Scarmeas, Nikolaos , Soldan, Anja , Udeh‐Momoh, Chinedu , Vemuri, Prashanthi , Vuoksimaa, Eero , Workgroup, and the Reserve, Resilience and Protective Factors PIA Empirical Definitions and Conceptual Frameworks, Lim, Yen Ying , Ossenkoppele, Rik , Morbelli, Silvia , Clouston, Sean , Martínez‐Lage, Pablo , Arenaza-Urquijo, Eider M, Vemuri, Prashanthi , Clouston, Sean A P , Franzmeier, Nicolai , Ossenkoppele, Rik , Stern, Yaakov , Arenaza‐Urquijo, Eider M. , Bartrés‐Faz, David , Kremen, William S. , Valenzuela, Michael , Workgroup, and the Reserve, Resilience and Protective Factors PIA Empirical Definitions and Conceptual Frameworks

Mayo Clinic

Alzheimer's & Dementia | September 15, 2018 | Volume: 16 | Issue: 9 | Pages: 1305-1311

10.1016/j.jalz.2018.07.219 | PMID 30222945 Get It

Abstract Several concepts, which in the aggregate get might be used to account for “resilience” against age‐ and disease‐related changes, have been the subject of much research. These include brain reserve, cognitive reserve, and brain maintenance. However, different investigators have use these terms in different ways, and there has never been an attempt to arrive at consensus on the definition of these concepts. Furthermore, there has been confusion regarding the measurement of these constructs and the appropriate ways to apply them to research. Therefore the reserve, resilience, and protective factors professional interest area, established under the auspices of the Alzheimer's Association, established a whitepaper workgroup to develop consensus definitions for cognitive reserve, brain reserve, and brain maintenance. The workgroup also evaluated measures that have been used to implement these concepts in research settings and developed guidelines for research that explores or utilizes these concepts. The workgroup hopes that this whitepaper will form a reference point for researchers in this area and facilitate research by supplying a common language.
FA02.07: BARRIER STRUCTURE AND FUNCTION OF THE NEO-SQUAMOUS EPITHELIUM FOLLOWING SUCCESSFUL BARRETT’S ENDOTHERAPY IS IMPAIRED
Ravindran, Adharsh, Blevins, Christopher H. , Johnson, Michele L., Lansing, Ramona, Katzka, David A. , Iyer, P. K. R., Wang, Kenneth , Iyer, Prasad

Mayo Clinic

Diseases of the Esophagus | September 14, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 5-5

10.1093/dote/doy089.fa02.07 Get It

Abstract Background The neo-squamous epithelium that replaces columnar epithelium after successful endoscopic ablation of Barrett's esophagus (BE) has not been fully characterized in regard to its structural and functional integrity. Intercellular space is a surrogate marker for epithelial structural integrity and mucosal impedance (MI) is a surrogate for transepithelial resistance and thus epithelial functional integrity. Impairment of the structural and functional integrity may influence recurrence following successful ablation. We aimed to measure the esophageal epithelial intercellular space diameter and MI in the neo-squamous and normal squamous epithelium of patients who underwent successful radiofrequency ablation for dysplastic BE. Methods Forty patients with complete remission of intestinal metaplasia (CRIM) (defined as two negative surveillance endoscopies for intestinal metaplasia) were prospectively recruited. Patients were excluded if they had endoscopic evidence of esophagitis. MI measurements were taken at 1 cm above the GE junction and 2 cm above the prior BE segment (targeting uninvolved squamous epithelium), using a novel through the scope MI probe. Endoscopic biopsies were also taken at these corresponding sites to assess intercellular space diameter using transmission electron microscopy (TEM) using standard techniques. Results 80% of patients were male with a mean age of 69 years. Mean follow since achieving CRIM was 30 months. 39 patients underwent RFA for dysplasia. The mean intercellular space diameter was higher in the neo-squamous epithelium (1.01 μm) when compared to the untreated native squamous epithelium (0.96 μm) [Difference of 0.056 μm, 95% CI of -0.036 to 0.148, P = 0.228]. The mean MI was significantly lower in the neosquamous epithelium (4001.3 Ω) when compared to the untreated native epithelium (5168.1 Ω) [Difference of 1166.7 Ω, 95% CI 418.8 to 1914.6, P = 0.003]. Conclusion Neo-squamous epithelium that replaces BE epithelium following successful endoscopic therapy for BE appears to be functionally and likely structurally deficient with regards to acid reflux barrier function, when compared to native squamous esophageal epithelium. This impairment may be associated with recurrence following successful ablation. Disclosure All authors have declared no conflicts of interest.
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
Jalali, Shahrzad , Price-Troska, Tammy, Kim, Hyo-Jin , Yang, Zhi‐Zhang, Novak, Anne J. , Ansell, Stephen M. , Villasboas, Jose, Paludo, Jonas , Villasboas, José C.

Mayo Clinic

Blood Advances | September 14, 2018 | Volume: 2 | Issue: 15 | Pages: 1985-1997

10.1182/bloodadvances.2018021113 | PMID 30104397 Get It

Key Points Cytokines in the BM microenvironment regulate PD-1 ligand expression and secretion in WM. Secreted PD-1 ligands modulate T-cell function in WM.
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
Tefferi, Ayalew , Nicolosi, Maura , Penna, Domenico , Mudireddy, Mythri , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Szuber, Natasha , Lasho, Terra L. , Ketterling, Rhett P.

Mayo Clinic

Blood Advances | September 14, 2018 | Volume: 2 | Issue: 15 | Pages: 1980-1984

10.1182/bloodadvances.2018018051 | PMID 30097464 Get It

Key PointsSerum albumin and cholesterol levels predict survival in primary myelofibrosis, independent of each other and contemporary risk models. The cachexia index, determined by serum albumin and cholesterol levels, might further refine current prognostic models in myelofibrosis.
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Kim, Sunghee , Go, Alan S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Singer, Daniel E. , Thomas, Laine , Blanco, Rosalia , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and, Jackson, Larry R. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Patients and

Mayo Clinic

Journal of the American Heart Association | September 14, 2018 | Volume: 7 | Issue: 16 | Pages: No page available

10.1161/jaha.118.008764 | PMID 30369317 Get It

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these “low‐risk” patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low‐risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P <0.0001). Stroke rates were low overall and ranged from 0 per 100 patient‐years in those with CHA 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5–1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4–1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6–1.9]) in CHA 2 DS 2 VASc ≥2. All‐cause mortality (per 100 patient‐years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8–2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1–1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7–1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4–6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0‐1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0‐1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.